Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JP-1366 · 2 trials · 2 indications
The proportion of subjects with remission on endoscopy at 8-week
| Arm | Type | Description |
|---|---|---|
| JP-1366 10 mg | EXPERIMENTAL | - |
| Lanston Capsule 15 mg | ACTIVE_COMPARATOR | - |
| Experimental Group | EXPERIMENTAL | JP-1366 20mg + Esomeprazole 40mg(placebo) |
| Active Comparative Group | ACTIVE_COMPARATOR | JP-1366 20mg(placebo) + Esomeprazole 40mg |
| Name | Type | Description |
|---|---|---|
| JP-1366 10 mg | DRUG | JP-1366 10 mg, tablet, orally once a day for up to 24 weeks |
| Lanston Capsule 15 mg | DRUG | Lanston Capsule 15 mg orally once a day for up to 24 weeks |
| JP-1366 10 mg placebo | DRUG | JP-1366 10 mg placebo, tablet, orally once a day for up to 24 weeks |
| Lanston Capsule 15 mg placebo | DRUG | Lanston Capsule 15 mg placebo, orally once a day for up to 24 weeks |
| JP-1366 20mg | DRUG | 1 capsule of JP-1366 20 mg, 1 tablet of esomeprazole placebo (irrespective of meals) |
| Esomeprazole 40mg | DRUG | 1 capsule of JP-1366 placebo, 1 tablet of esomeprazole 40 mg placebo (irrespective of meals) |
Inclusion Criteria: 1. Adult male/female aged 19 years or older as of the date of obtaining consent 2. Those who are diagnosed with musculoskeletal diseases such as rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, or other diseases at the time of screening and require continuous admini...
JP-1366 is an investigational small molecule being developed for erosive esophagitis and peptic ulcer, both gastrointestinal conditions. It is currently in Phase 3 clinical development and has not been approved by the FDA.
JP-1366 is being developed by cbdMD, Inc., which trades under the ticker YCBD. The company is conducting Phase 3 trials for the drug in South Korea.
JP-1366 is in Phase 3 clinical development. It is an investigational drug and has not received FDA approval. Two Phase 3 trials have been conducted or are ongoing, with one completed and one currently recruiting.
JP-1366 has two Phase 3 trials. NCT05443984 compared JP-1366 20mg to esomeprazole 40mg in erosive esophagitis and is completed. NCT06439563 is recruiting to evaluate JP-1366 in preventing NSAID-induced peptic ulcers. Both trials are in South Korea.
JP-1366 is also known as JP-1366 10 mg. This alternative name refers to a specific dosage strength of the drug, which is being investigated in clinical trials for gastrointestinal conditions.